Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors

Lignende værker

• Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives
  af: Lu, Dong, et al.
  Udgivet: (2017)
• The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
  af: Zhang, Xuan, et al.
  Udgivet: (2013)
• Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR
  af: Wu, Jianwei, et al.
  Udgivet: (2013)
• Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)
  af: Zang, Hongjing, et al.
  Udgivet: (2020)
• Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors
  af: Longjia Yan, et al.
  Udgivet: (2022-12-01)